Pharma BD Deal Intelligence
ArQule's $95M stock-and-cash acquisition of Camitro to bolt on in silico ADMET modeling for its discovery engine was a bust: the technology was never commercialized, and ArQule shuttered the Camitro sites and cut roughly 31% of its workforce within two years.
ArQule paid ~$84M in stock for Camitro's ADMET modeling tech, never commercialized it, and shut the acquired operations within two years.
Full analysis, sources & comparables →ArQule completed its acquisition of Camitro, adding an integrated platform of predictive ADME/Tox modeling technologies for the design of pharmaceutical drug…
ArQule (Woburn, MA) acquired privately-held Camitro (Menlo Park, CA / Cambridge, UK), an in silico ADMET modeling company, for ~$85M closing value (3.4M shares…
ArQule completed a $95M merger with Camitro Corporation as the initial major step in CEO Stephen Hill's pivot from chemistry services to biopharmaceutical drug…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
ArQule acquired Camitro Corporation, an in silico ADME/Tox modeling company, in a stock-and-cash merger valued at ~$95M (announced; ~$85M at close: 3.4M ArQule shares + $1.7M cash). The deal integrated predictive ADMET into ArQule's parallel-synthesis discovery engine as CEO Stephen Hill pivoted from chemistry services toward drug discovery; ArQule ultimately could not commercialize the technology, leading to site closures and layoffs.
ArQule paid ~$84M in stock for Camitro's ADMET modeling tech, never commercialized it, and shut the acquired operations within two years.
Assessment window: 15yr post-close.
ADMET (absorption, distribution, metabolism, elimination, toxicity) liabilities account for the majority of late-stage clinical attrition in small-molecule drug development. In silico ADMET modeling aims to predict these properties from chemical structure to cull liabilities pre-synthesis, reducing the cost and timeline of moving from hit to development candidate.
By early 2001 the in silico ADMET / predictive computational chemistry niche included specialist platforms from Accelrys (post-Pharmacopeia spin-out merger), Lion Bioscience, Tripos, Simulations Plus (GastroPlus), MDL Information Systems, and academic-licensed tools such as Schrödinger and OpenEye — most sold as enterprise software to pharma R&D rather than embedded in integrated discovery operations. ArQule, historically a chemistry-services and parallel-synthesis house under outgoing founder Eric Gordon, was repositioning under new CEO Stephen Hill toward a fully integrated drug-discovery model after a $65.7M November 2000 secondary offering. The February 1, 2001 acquisition of Camitro Corporation (Menlo Park, CA + Cambridge, UK) for ~$95M (3.4M ArQule shares plus $1.7M cash; https://www.nature.com/articles/nbt0301_191a) integrated Camitro's high-throughput ADMET modeling platform into ArQule's Parallel Track Drug Discovery program, with CEO Stephen Hill arguing 'Early drug discovery — using high throughput, automated in vitro and in silico methods, must become the primary testing ground for novel compounds — not clinical development.' Gerard Klauer Mattison analyst Ivonne Marondel projected Camitro would generate ~$35M in software sales by end-2002. The transformation thesis ultimately failed: ArQule was unable to commercialize the Camitro platform, sold the ADME capability to Inpharmatica in 2003 (rebranded Admensa Interactive), and laid off 128 staff while closing the Redwood City and Cambridge sites. The deal is retained as a strategically notable marker of early-2000s computational-chemistry M&A.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| ArQule Inc. / Camitro Corporation (this deal) | 2001 | $95M | 11 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
← Browse all deals · How we score deals
More: 2001 deals